A Serum MicroRNA Signature Predicts Trastuzumab Benefit in HER2-positive Metastatic Breast Cancer Patients

Overview

Journal Nat Commun

Specialty Biology

Date 2018 Apr 26

PMID 29691399

Citations 59

Authors

Huiping Li

Jiang Liu

Jianing Chen

Huiyun Wang

Linbin Yang

Fei Chen

Siting Fan

Jing Wang

Bin Shao

Dong Yin

Musheng Zeng

Mengfeng Li

Jun Li

Fengxi Su

Qiang Liu

Herui Yao

Shicheng Su

Erwei Song

Affiliations

Soon will be listed here.

Abstract

Trastuzumab is a standard treatment for HER2-positive (HER2) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2 metastatic breast cancer (MBC) patients remains unclear. Using miRNA microarray, we identify 13 differentially expressed miRNAs in the serum of HER2 MBC patients with distinct response to trastuzumab, and four miRNAs are selected to construct a signature to predict survival using LASSO model. Further, our data show that miR-940 is mainly released from the tumor cells and miR-451a, miR-16-5p and miR-17-3p are mainly from the immune cells. All these four miRNAs directly target signaling molecules that play crucial roles in regulating trastuzumab resistance. In summary, we develop a serum-based miRNA signature that potentially predicts the therapeutic benefit of trastuzumab for HER2 MBC patients and warrants future validation in prospective clinical trials.

Citing Articles

Resistance mechanisms and prospects of trastuzumab.

Wang L, Wang Y, Li Y, Zhou L, Du J, Wang J Front Oncol. 2024; 14:1389390.

PMID: 39655080 PMC: 11625751. DOI: 10.3389/fonc.2024.1389390.

Circulating Micro-RNAs Predict the Risk of Recurrence in Triple-Negative Breast Cancer.

Kujala J, Tengstrom M, Heikkinen S, Taipale M, Kosma V, Hartikainen J Cells. 2024; 13(22).

PMID: 39594632 PMC: 11593277. DOI: 10.3390/cells13221884.

miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential of Plasma Exosomal miR-6855-5p as an Indicator of Radiosensitivity in Patients with....

Ueda H, Takahashi H, Kobayashi S, Kubo M, Sasaki K, Iwagami Y Ann Surg Oncol. 2024; 32(2):720-735.

PMID: 39269634 DOI: 10.1245/s10434-024-16115-w.

Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.

Kubeczko M, Tudrej P, Tyszkiewicz T, Krzywon A, Oczko-Wojciechowska M, Jarzab M Oncol Lett. 2024; 27(4):181.

PMID: 38464342 PMC: 10921259. DOI: 10.3892/ol.2024.14314.

Multi-omics reveals deoxycholic acid modulates bile acid metabolism via the gut microbiota to antagonize carbon tetrachloride-induced chronic liver injury.

Zhang L, Zheng Z, Huang H, Fu Y, Chen T, Liu C Gut Microbes. 2024; 16(1):2323236.

PMID: 38416424 PMC: 10903553. DOI: 10.1080/19490976.2024.2323236.

References

Stanton S, Disis M . Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016; 4:59. PMC: 5067916. DOI: 10.1186/s40425-016-0165-6. View

Zhang M, Li S, Huang G, Lin G, Shuang Z, Lao X . Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer. 2015; 15:64. PMC: 4344737. DOI: 10.1186/s12885-015-1067-6. View

Kroh E, Parkin R, Mitchell P, Tewari M . Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50(4):298-301. PMC: 4186708. DOI: 10.1016/j.ymeth.2010.01.032. View

Liu N, Chen N, Cui R, Li W, Li Y, Wei R . Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. DOI: 10.1016/S1470-2045(12)70102-X. View

Bagnoli M, Canevari S, Califano D, Losito S, Di Maio M, Raspagliesi F . Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 2016; 17(8):1137-1146. DOI: 10.1016/S1470-2045(16)30108-5. View

Wei R, Huang G, Zhang M, Li B, Zhang H, Shi M . Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res. 2013; 19(17):4780-91. DOI: 10.1158/1078-0432.CCR-12-2728. View

Luen S, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E . Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2016; 18(1):52-62. PMC: 5477653. DOI: 10.1016/S1470-2045(16)30631-3. View

Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen A . Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2010; 29(3):264-71. DOI: 10.1200/JCO.2010.30.8213. View

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

10.

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y . Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-6. DOI: 10.1200/JCO.2009.24.9342. View

11.

Zhang S, Huang W, Li P, Guo H, Poh S, Brady S . Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011; 17(4):461-9. PMC: 3877934. DOI: 10.1038/nm.2309. View

12.

Su S, Liu Q, Chen J, Chen J, Chen F, He C . A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014; 25(5):605-20. DOI: 10.1016/j.ccr.2014.03.021. View

13.

Valero V, Forbes J, Pegram M, Pienkowski T, Eiermann W, von Minckwitz G . Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active.... J Clin Oncol. 2010; 29(2):149-56. DOI: 10.1200/JCO.2010.28.6450. View

14.

Park S, Jiang Z, Mortenson E, Deng L, Radkevich-Brown O, Yang X . The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010; 18(2):160-70. PMC: 2923645. DOI: 10.1016/j.ccr.2010.06.014. View

15.

Zou X, You R, Liu H, He Y, Xie G, Xie Z . Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017; 77:117-126. DOI: 10.1016/j.ejca.2017.02.029. View

16.

Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M . Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat. 2014; 147(1):61-8. DOI: 10.1007/s10549-014-3079-3. View

17.

Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C . Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. Oncologist. 2011; 16(11):1535-46. PMC: 3233287. DOI: 10.1634/theoncologist.2011-0165. View

18.

Loi S, Dafni U, Karlis D, Polydoropoulou V, Young B, Willis S . Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. JAMA Oncol. 2016; 2(8):1040-7. DOI: 10.1001/jamaoncol.2016.0339. View

19.

Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S . Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2009; 11(2):136-46. PMC: 4299826. DOI: 10.1016/S1470-2045(09)70343-2. View

20.

Pritchard C, Kroh E, Wood B, Arroyo J, Dougherty K, Miyaji M . Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2011; 5(3):492-497. PMC: 4186243. DOI: 10.1158/1940-6207.CAPR-11-0370. View